巨噬细胞及其外泌体microRNAs在肝病中的作用

摘要/Abstract

摘要： 巨噬细胞作为一种重要的先天性免疫细胞,广泛参与多种肝病的炎症反应、免疫调节、免疫耐受等过程。外泌体(exosomes,Exos)作为具有双层膜结构的天然载体,可富集多种生物活性物质,实现维持稳态、细胞间物质及信号传递、抗原提呈等功能。其中,Exos携带的微小RNAs(miRNAs)通过调控下游信号通路在多种肝病中发挥关键作用,已逐渐成为新兴的重要非侵入性肝病检测手段和治疗靶点。本文就巨噬细胞及其来源Exos携带的miRNAs在肝病中的作用进行综述,希望为肝病的临床诊断及治疗提供新靶点和新思路。

关键词: 巨噬细胞, 外泌体, 肝脏疾病, 微小RNAs

卢旺, 白丽, 陈煜. 巨噬细胞及其外泌体microRNAs在肝病中的作用[J]. 肝脏, 2022, 27(7): 733-737.

参考文献

[1] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol, 2019,70:151-171.
[2] Hilscher MB, Shah VH. A NET gain in our understanding of acute liver failure. Hepatology, 2022,75:511-513.
[3] von Meijenfeldt FA, Stravitz RT, Zhang J, et al. Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome. Hepatology, 2022,75:623-633.
[4] Wang C, Ma C, Gong L, et al. Macrophage Polarization and Its Role in Liver Disease. Front Immunol,2021,12:803037.
[5] Garcia-Martin R, Wang G, Brandao BB, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature,2022,601:446-451.
[6] Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol,2019,4:545-558.
[7] Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology,2015,61:77-87.
[8] Boltjes A, van Montfoort N, Biesta PJ, et al. Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. J Infect Dis,2015,211:1268-1278.
[9] Movita D, van de Garde MD, Biesta P, et al. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. J Virol,2015,89:4809-4817.
[10] Shrivastava S, Mukherjee A, Ray R, et al. Hepatitis C virus induces interleukin-1beta (IL-1beta)/IL-18 in circulatory and resident liver macrophages. J Virol,2013,87:12284-12290.
[11] Faure-Dupuy S, Delphin M, Aillot L, et al. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J Hepatol,2019,71:1086-1098.
[12] Li J, Liu K, Liu Y, et al. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nat Immunol,2013,14:793-803.
[13] Wu W, Wu D, Yan W, et al. Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p. J Infect Dis, 2021,223:686-698.
[14] Zhou Y, Wang X, Sun L, et al. Toll-like receptor 3-activated macrophages confer anti-HCV activity to hepatocytes through exosomes. FASEB J,2016,30:4132-4140.
[15] Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology,2019,69:2672-2682.
[16] Krenkel O, Puengel T, Govaere O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology,2018,67:1270-1283.
[17] Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology,2018,67:1754-1767.
[18] Svendsen P, Graversen JH, Etzerodt A, et al. Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes. Mol Ther Methods Clin Dev,2017,4:50-61.
[19] Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther,2016,44:1183-1198.
[20] Hou X, Yin S, Ren R, et al. Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis. Hepatology,2021,74:116-132.
[21] Hou J, Zhang J, Cui P, et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest,2021,131.
[22] Cui K, Yan G, Xu C, et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1beta in mice. J Hepatol,2015,62:1311-1318.
[23] de Carvalho Ribeiro M, Szabo G. Role of the Inflammasome in Liver Disease. Annu Rev Pathol,2022,17:345-365.
[24] Choudhury A, Bullock D, Lim A, et al. Inhibition of HSP90 and Activation of HSF1 Diminish Macrophage NLRP3 Inflammasome Activity in Alcohol-Associated Liver Injury. Alcohol Clin Exp Res,2020,44:1300-1311.
[25] Zhou Y, Wu M, Xu L, et al. Bmal1 Regulates Macrophage Polarize Through Glycolytic Pathway in Alcoholic Liver Disease. Front Pharmacol,2021,12:640521.
[26] Wang Z, Zhang X, Zhu L, et al. Inulin alleviates inflammation of alcoholic liver disease via SCFAs-inducing suppression of M1 and facilitation of M2 macrophages in mice. Int Immunopharmacol,2020,78:106062.
[27] Lee JH, Shim YR, Seo W, et al. Mitochondrial Double-Stranded RNA in Exosome Promotes Interleukin-17 Production Through Toll-Like Receptor 3 in Alcohol-associated Liver Injury. Hepatology,2020,72:609-625.
[28] Babuta M, Furi I, Bala S, et al. Dysregulated Autophagy and Lysosome Function Are Linked to Exosome Production by Micro-RNA 155 in Alcoholic Liver Disease. Hepatology,2019,70:2123-2141.
[29] Chen L, Yao X, Yao H, et al. Exosomal miR-103-3p from LPS-activated THP-1 macrophage contributes to the activation of hepatic stellate cells. FASEB J,2020,34:5178-5192.
[30] Chen L, Huang Y, Duan Z, et al. Exosomal miR-500 Derived From Lipopolysaccharide-Treated Macrophage Accelerates Liver Fibrosis by Suppressing MFN2. Front Cell Dev Biol,2021,9:716209.
[31] Hu M, Wang Y, Liu Z, et al. Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. Nat Nanotechnol,2021,16:466-477.
[32] Ji K, Fan M, Huang D, et al. Clodronate-nintedanib-loaded exosome-liposome hybridization enhances the liver fibrosis therapy by inhibiting Kupffer cell activity. Biomater Sci, 2022,10:702-713.
[33] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin,2021,71:209-249.
[34] Liu G, Ouyang X, Sun Y, et al. The miR-92a-2-5p in exosomes from macrophages increases liver cancer cells invasion via altering the AR/PHLPP/p-AKT/beta-catenin signaling. Cell Death Differ,2020,27:3258-3272.
[35] Li W, Xin X, Li X, et al. Exosomes secreted by M2 macrophages promote cancer stemness of hepatocellular carcinoma via the miR-27a-3p/TXNIP pathways. Int Immunopharmacol, 2021,101:107585.
[36] Tian B, Zhou L, Wang J, et al. miR-660-5p-loaded M2 macrophages-derived exosomes augment hepatocellular carcinoma development through regulating KLF3. Int Immunopharmacol,2021,101:108157.
[37] Bai ZZ, Li HY, Li CH, et al. M1 Macrophage-Derived Exosomal MicroRNA-326 Suppresses Hepatocellular Carcinoma Cell Progression Via Mediating NF-kappaB Signaling Pathway. Nanoscale Res Lett,2020,15:221.
[38] Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, et al. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials, 2021,278:121137.
[39] Jiang L, Zhang S, Hu H, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acute liver failure by reducing the activity of the NLRP3 inflammasome in macrophages. Biochem Biophys Res Commun,2019,508:735-741.
[40] Wu R, Fan X, Wang Y, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. Front Immunol,2022,13:833878.
[41] Kawata R, Oda S, Koya Y, et al. Macrophage-derived extracellular vesicles regulate concanavalin A-induced hepatitis by suppressing macrophage cytokine production. Toxicology,2020,443:152544.